Genomic insight without raw data custody
MyDNABank helps CROs and clinical development teams discover and request access to consented genomic cohorts through a standards-based, governed model. Raw participant data is not downloaded or handed over.
Precision medicine programmes need genomic data, but raw data movement creates risk
CROs and clinical trial teams need high-quality genomic data with clear, enforceable consent. Current access models are often fragmented, slow, inconsistent and difficult to govern.
Data silos
Useful cohorts sit across institutions, labs, biobanks and consumer platforms.
Consent complexity
Commercial research permissions need to be clear, traceable and enforceable.
Slow feasibility
Teams often cannot assess cohort availability before expensive access work begins.
Custody exposure
Taking possession of raw data increases governance, security and liability burden.
Genomic cohorts for research — without taking custody
MyDNABank provides governed access to consented genomic data. This supports genetic stratification, target validation and pharmacogenomic exploration while keeping raw data under controlled pathways.
Genetic stratification
Identify genetically defined subgroups within consented cohorts for trial design and enrichment discussions.
Target support
Explore whether genetic variation in consented cohorts supports a proposed drug target.
Pharmacogenomic signals
Examine gene–drug related genetic variation under a governed access model.
Research-ready genomic structure
Genomic data and consent metadata organised for searchable feasibility and controlled analysis workflows.
Built for CRO and clinical trial workflows
MyDNABank supports approved commercial research where cohort discovery, consent, analysis and outputs need strong governance — based on genomic data and consent metadata.
Drug target validation
Test whether genetic variation supports a target in consented genomic cohorts.
Genomic biomarker exploration
Explore genetic patterns in consented cohorts that may inform biomarker hypotheses.
Clinical trial enrichment
Find genetically stratified populations before recruitment.
Pharmacogenomics
Study gene–drug related genetic variation across approved cohorts.
Companion diagnostics
Early support for discovery of genetically defined patient groups that may inform companion diagnostic research.
How governed access works
MyDNABank is designed around cohort discovery, consent-aware access, controlled analysis and approved research outputs.
Discover cohorts
Search structured genomic profiles and consent metadata to evaluate cohort feasibility.
Review consent
Confirm whether the intended commercial or research use aligns with participant consent scope.
Run approved analysis
Approved workflows run inside a governed environment designed around controlled analysis.
Receive permitted outputs
Researchers receive approved outputs and findings without unmanaged raw data transfers.
Discuss a collaboration
Tell us about your trial or research programme — and whether you need feasibility, enrichment, target validation, pharmacogenomics or governed analysis.
Governed genomic access for clinical development
Discuss cohort feasibility, trial enrichment, target validation, pharmacogenomics or controlled analysis with the MyDNABank team.